Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
jRCTs031190186Recruiting
Randomised trial of capecitabine and oxaliplatin in colorectal cancer (CRC) (3 arms), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoint: Relapse-free survival. Started Jan 2020; status: recruiting.
Beyond the preview
Study design, results and competitive context are available in the Gosset platform where reported.
Available in the Gosset platform where reported.
Available in the Gosset platform where reported.
See how Gosset can support your research on jRCTs031190186.